2016-10-14 19:50:34 UTC

Incorporate the Latest IBD Advances into Your Practice

Oct. 18, 2016

Join experts for a free regional dinner presentation focusing on incorporating the latest evidence-based advances in IBD care into your practice.

Supported by an educational grant from Takeda Pharmaceuticals U.S.A. Inc., AGA Institute and the North American Center for Continuing Medical Education (NACCME) are putting together a series of free regional dinner presentations on the latest evidence-based advances in IBD care.

The program, "Advancing IBD Practice in Our Communities: A Focus on Evidence-based Care" will take place in New York on Nov. 29, Chicago on Dec. 13, and Houston on Jan. 18. Pose your most pressing IBD-related questions and weigh in as faculty debate challenging IBD cases.

The first presentation, in New York, will take place on Tuesday, Nov. 29, from 6:30 to 8 p.m. at Morton's The Steakhouse at 551 5th Avenue. Raymond Cross, MD, MS, AGAF, and Millie D. Long, MD, MPH, will present. To register, click here.

Be sure to make time for these free events.
Participants will receive 1 AMA PRA Category 1 Credit™ and 1 Contact Hour for nurses.

Learning objectives include:

  • Implementing guideline- and evidence-based strategies to optimize the assessment of IBD.
  • Prevention and monitoring of associated complications and comorbidities.
  • Describing currently approved biologic treatments for IBD, as well as their inflammatory pathway targets and placement within the IBD treat-to-target algorithm.
  • Translating clinical evidence of biologic therapeutic approaches into the early and effective management of IBD. 

More on Crohn's Disease

Attend the AGA Postgraduate Course for Practical, Take Home Information

Feb. 12, 2018

Join us on June 2-3 in Washington, D.C. This course is held in conjunction with Digestive Disease Week® (DDW) 2018.

Building an IBD Specialty Clinic from the Ground Up

Feb. 7, 2018

Gastro One in Tennessee developed an IBD clinic within their practice, which decreased emergency room visits by 70 percent.

4 New & Noteworthy IBD Drug Studies

Jan. 30, 2018

We recommend reviewing these four abstracts from the Crohn’s & Colitis Congress to keep informed on IBD treatment options.